Tocilizumab and Rituximab in Systemic Sclerosis: A Real-Life Retrospective Observational Study Across Different Clinical Phenotypes
Journal of Personalized Medicine · 30.03.2026 · 16 (4) · 186
DOI: 10.3390/jpm16040186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 30.03.2026. Verfasst von Silvia Cavalli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To describe the efficacy and safety of tocilizumab (TCZ) and rituximab (RTX) in real-world patients with systemic sclerosis (SSc), across different clinical phenotypes and lines of therapy, evaluating both global clinical outcomes and lung function.
Methods
SSc patients treated with TCZ (n = 27) or RTX (n = 23) were retrospectively followed for 12–24 months. Clinical measures, including modified Rodnan Skin Score (mRSS), C-reactive protein (CRP), and revised EUSTAR activity index 2017 (RAI), as well as spirometric parameters, were recorded at baseline and 6, 12, and 24 months. Statistical methods for repeated measures were applied to investigate outcome trends. Given the baseline differences, between-group comparisons were considered exploratory.
Results
RTX was used earlier in disease course, while TCZ was mainly used as a rescue therapy. In both groups, mRSS, CRP levels and RAI significantly decreased over time. RTX-treated patients showed a greater absolute mRSS improvement, in line with higher baseline skin scores. No treatment discontinuations due to adverse events occurred in either group; one death and one discontinuation due to inefficacy were observed in the TCZ group. Among SSc-ILD patients, FVC% showed a modest decline in both groups, while DLCO% remained overall stable, and only a few patients met the OMERACT criteria for functional progression.
Conclusions
In this real-world, single-center cohort of SSc patients, both agents were associated with a positive impact on disease activity, with a low rate of lung progression and with favorable safety profiles. Owing to substantial baseline imbalances and confounding by indication, between-group comparisons do not allow firm conclusions on comparative effectiveness. Overall, these data support the use of both agents in different clinical scenarios.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.
- Scleroderma Clinic, Clinical Rheumatology Unit, ASST Gateano Pini-CTO, 20122 Milan, Italy.
ORCID-Profile: Silvia Cavalli, Maria Rosa Pellico, Giorgia Trignani, Manuel Sette, Claudia Iannone, Roberto Caporali, Nicoletta Del Papa
Zitieren
APA
Cavalli, S., Pellico, M. R., Trignani, G., Sette, M., Iannone, C., Caporali, R., & Del Papa, N. (2026). Tocilizumab and Rituximab in Systemic Sclerosis: A Real-Life Retrospective Observational Study Across Different Clinical Phenotypes. Journal of Personalized Medicine, 16(4), 186. https://doi.org/10.3390/jpm16040186
Vancouver
Cavalli S, Pellico MR, Trignani G, Sette M, Iannone C, Caporali R, et al. Tocilizumab and Rituximab in Systemic Sclerosis: A Real-Life Retrospective Observational Study Across Different Clinical Phenotypes. Journal of Personalized Medicine. 2026;16(4):186. doi:10.3390/jpm16040186
BibTeX
@article{Cavalli2026,
author = {Cavalli, Silvia and Pellico, Maria Rosa and Trignani, Giorgia and Sette, Manuel and Iannone, Claudia and Caporali, Roberto and Del Papa, Nicoletta},
title = {Tocilizumab and Rituximab in Systemic Sclerosis: A Real-Life Retrospective Observational Study Across Different Clinical Phenotypes},
journal = {Journal of Personalized Medicine},
year = {2026},
volume = {16},
number = {4},
pages = {186},
doi = {10.3390/jpm16040186}
}
EUVIMED